Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable…

Overview of attention for article published in Journal of Clinical Oncology, October 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

news: 7 news outlets
blogs: 1 blog
twitter: 29 X users

patent: 3 patents
facebook: 1 Facebook page
guideline: 2 clinical guideline sources

Readers on

mendeley: 419 Mendeley

So far, Altmetric has seen 9 news stories from 7 outlets.

Oncolytic Virus Plus Ipilimumab Improves Responses in Advanced Melanoma

UBM Medica, 27 Jun 2018

Jun 27, 2018 The combination of an oncolytic virus known as talimogene laherparepvec with ipilimumab yielded a significantly…

Melanoma avanzato, promettente la combinazione T-VEC piu ipilimumab

Pharmastar Italy, 16 Nov 2017

La combinazione di un virus oncolitico - talimogene laherparepvec - più un inibitore dei checkpoint immunitari – ipilimumab …

Melanoma avanzato, promettente la combinazione T-VEC piu ipilimumab

Pharmastar Italy, 16 Nov 2017

La combinazione di un virus oncolitico - talimogene laherparepvec - più un inibitore dei checkpoint immunitari – ipilimumab …

Oncolytic Virus Succeeds in Melanoma Trial

MedPage Today, 01 Nov 2017

Action Points Note that this randomized trial found a better objective response rate when patients with unresectable melanoma…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 5 additional news stories.